Latest News and Press Releases

PARIS, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...

PARIS, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...

PARIS, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...

Combination with checkpoint inhibitors decreased tumor growth rate and prolonged survival in syngeneic HCC mouse model PARIS & COPENHAGEN, Denmark--(BUSINESS...

· Clinical development plan in line with objectives · Livatag® on track to deliver its next important milestone with 90% of patients randomized · €12.5m capital increase successfully...

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized in the development of orphan oncology therapeutics,...

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the...

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News: Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO): THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, OR...

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, OR AUSTRALIA THIS PRESS RELEASE IS NOT INTENDED AS AN OFFER AND IS FOR INFORMATION PURPOSES ONLY PARIS &...

· Livatag® Nanoformulation Leads to Increased Exposure and Preferential Affinity for Liver, Supporting Current Relive Phase III Study Rationale · Demonstrates Enhanced Effect in Combination with...